TRDA Latest Press Releases

-- October 21, 2026 --

Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer Globe Newswire 7:00 AM

-- October 14, 2026 --

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study Globe Newswire 7:00 AM

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 Globe Newswire 7:00 AM

-- September 10, 2026 --

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program Globe Newswire 7:00 AM

-- September 2, 2026 --

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- August 5, 2026 --

Entrada Therapeutics Reports Second Quarter 2026 Financial Results Globe Newswire 7:00 AM

-- June 2, 2026 --

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study Globe Newswire 7:00 AM

-- June 1, 2026 --

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- May 26, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA Globe Newswire 5:33 PM

Market Data Delayed 15 Minutes